Comparative Pharmacology
Head-to-head clinical analysis: MAXIPIME versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXIPIME versus RESPORAL.
MAXIPIME vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It has enhanced activity against Gram-negative bacteria due to rapid penetration through the outer membrane and low affinity for β-lactamases.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
1-2 g IV every 8-12 hours for most indications; maximum 2 g every 8 hours for severe infections.
2 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 2-2.5 hours in adults with normal renal function; extends to 8-12 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 20-24 hours in severe impairment (CrCl < 30 mL/min).
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Primarily renal (approximately 80-90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal excretion is minimal (< 1%).
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic